Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations

BACKGROUND: Afatinib is an irreversible ErbB family blocker that improves progression‐free survival (PFS) of advanced EGFR‐mutant lung adenocarcinoma compared to chemotherapy. However, afatinib leads to more adverse events than first‐generation EGFR inhibitors. Hence, exploration of the optimal afat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shouzheng, Xing, Puyuan, Yang, Ke, Hao, Xuezhi, Ma, Di, Mu, Yuxin, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558598/
https://www.ncbi.nlm.nih.gov/pubmed/31095895
http://dx.doi.org/10.1111/1759-7714.13095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558598/
https://www.ncbi.nlm.nih.gov/pubmed/31095895
http://dx.doi.org/10.1111/1759-7714.13095

Ejemplares similares